<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="article-commentary" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Exp Med</journal-id><journal-title>The Journal of Experimental Medicine</journal-title><issn pub-type="ppub">0022-1007</issn><issn pub-type="epub">1540-9538</issn><publisher><publisher-name>The Rockefeller University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10049938</article-id><article-id pub-id-type="pmc">2192956</article-id><article-categories><subj-group subj-group-type="heading"><subject>Commentaries</subject></subj-group></article-categories><title-group><article-title>CD4 T Cells and Their Role in Antitumor Immune Responses </article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Toes</surname><given-names>Ren&#x000e9; E.M.</given-names></name><xref ref-type="aff" rid="N0x41c8010N0x3da70b8">&#x0002a;</xref><xref ref-type="aff" rid="N0x41c8010N0x3da70b8">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Ossendorp</surname><given-names>Ferry</given-names></name><xref ref-type="aff" rid="N0x41c8010N0x3da70b8">&#x0002a;</xref></contrib><contrib contrib-type="author"><name><surname>Offringa</surname><given-names>Rienk</given-names></name><xref ref-type="aff" rid="N0x41c8010N0x3da70b8">&#x0002a;</xref></contrib><contrib contrib-type="author"><name><surname>Melief</surname><given-names>Cornelis J.M.</given-names></name><xref ref-type="aff" rid="N0x41c8010N0x3da70b8">&#x0002a;</xref></contrib></contrib-group><aff id="N0x41c8010N0x3da70b8">From the <label>&#x0002a;</label>Department of Immunohematology and Blood Bank, Leiden University Medical Center,  2333 AZ Leiden, The Netherlands; and <label>&#x02021;</label>Abteilung Immunologie, Institut f&#x000fc;r Zellbiologie,  D-72076 &#x02009;T&#x000fc;bingen, Germany</aff><author-notes><fn><p>Address correspondence to Ren&#x000e9; E.M. Toes, Department of Immunohematology and Blood Bank, Leiden  University Medical Center, P.O. Box 9600, 2333 AZ Leiden, The Netherlands. Phone: 31-71-5263800;  Fax: 31-71-5216751; E-mail: <email>r.e.m.toes&#x00040;immunohematology.medfac.leidenuniv.nl</email></p></fn></author-notes><pub-date pub-type="ppub"><day>1</day><month>3</month><year>1999</year></pub-date><volume>189</volume><issue>5</issue><fpage>753</fpage><lpage>756</lpage><history><date date-type="received"><day>13</day><month>1</month><year>1999</year></date></history><copyright-year>1999</copyright-year></article-meta></front><body><p>The specificity and power of the cellular arm of the immune system may provide new therapeutic approaches  to cancer. With the assumption that T cells might be able  to recognize and eliminate cancer cells with the same efficiency as virus-infected cells, investigators have searched  many years for ways to trigger or amplify the patient's inadequate immune response to tumors. Much attention has  been given to the role of CD8<sup>&#x0002b;</sup> CTLs because most tumors  are MHC class I positive, but negative for MHC class II.  Moreover, CD8<sup>&#x0002b;</sup> CTLs are able to lyse tumor cells directly  upon recognition of peptide&#x02013;MHC class I complexes expressed by the tumor, and their ability to eradicate large tumor masses in vivo has been demonstrated. The focus in  cancer immunology on CD8<sup>&#x0002b;</sup> T cell responses is also exemplified by an increasing list of tumor antigens identified  by tumor-reactive CD8<sup>&#x0002b;</sup> CTLs. CD4<sup>&#x0002b;</sup> Th cells have received far less attention, which is remarkable given the pivotal role of these cells in regulating most antigen-specific  immune responses. Until now, only a few Th epitopes derived from human tumor antigens recognized by CD4<sup>&#x0002b;</sup> Th  cells have been identified (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). Three studies published in  this issue describe the identification of melanoma antigens  that are recognized by CD4<sup>&#x0002b;</sup> T cells in the context of  MHC class II molecules (<xref ref-type="bibr" rid="B3">3</xref>&#x02013;<xref ref-type="bibr" rid="B5">5</xref>). Charting the Th response  against human melanoma as well as other tumors is important for the development of optimal anticancer vaccines  and for the design of other T cell&#x02013;related therapeutic modalities in cancer.</p><sec><title>Lessons Learned from Mouse Tumor Models.</title><p>Studies using  adoptively transferred purified T cell subsets or in vivo depletion studies have firmly established an important role for  tumor-specific CD8<sup>&#x0002b;</sup> CTLs in antitumor immunity (for a  review, see reference <xref ref-type="bibr" rid="B6">6</xref>). By comparing the relative contribution of CD4<sup>&#x0002b;</sup> and CD8<sup>&#x0002b;</sup> T cells to the overall immune  response, it was shown that activated adoptively transferred  CD8<sup>&#x0002b;</sup> T cells alone are as effective as adoptively transferred  CD4<sup>&#x0002b;</sup> and CD8<sup>&#x0002b;</sup> T cells, provided that IL-2 is given simultaneously (<xref ref-type="bibr" rid="B7">7</xref>&#x02013;<xref ref-type="bibr" rid="B9">9</xref>). Nonetheless, a critical contribution by  tumor-specific CD4<sup>&#x0002b;</sup> Th cells in the development of an effective antitumor tumor response was consistently found in  several murine tumor models (<xref ref-type="bibr" rid="B10">10</xref>&#x02013;<xref ref-type="bibr" rid="B13">13</xref>). CD4<sup>&#x0002b;</sup> T cells are  likely to play a diversified role in antitumor immunity that  includes several distinct antitumor effector functions. The  role of CD4<sup>&#x0002b;</sup> T cells in priming of CTLs is well documented (<xref ref-type="bibr" rid="B14">14</xref>), explaining why activated CTLs, but not naive  CTLs, can mediate potent antitumor effects in the absence  of CD4<sup>&#x0002b;</sup> T cells. Analysis of the participation of individual  T cell populations in the elimination of the Friend murine  leukemia virus (MuLV)&#x02013;induced tumor FBL-3, revealed  that tumor-specific CD4<sup>&#x0002b;</sup> T cells can also exert their effect  independently of CD8<sup>&#x0002b;</sup> CTLs. Adoptive transfer studies  showed that both the noncytolytic CD4<sup>&#x0002b;</sup> subset as well as  the cytolytic CD8<sup>&#x0002b;</sup> subset were individually capable of  eradication of disseminated leukemia in tumor-bearing  mice (for a review, see reference <xref ref-type="bibr" rid="B15">15</xref>). Thus, although the  tumor-specific MHC class II&#x02013;restricted CD4<sup>&#x0002b;</sup> T cells are  not able to recognize this MHC class II&#x02013;negative tumor directly, they are able to control tumor growth via a mechanism that does not require CTLs (<xref ref-type="bibr" rid="B16">16</xref>). More recently, it  was shown that not only adoptive transfer of CD4<sup>&#x0002b;</sup> T cells,  but also vaccination with an MuLV-derived Th epitope  (but not a control Th peptide) induced protection against a  subsequent challenge with MHC class II&#x02013;negative, virus-induced tumor cells (<xref ref-type="bibr" rid="B17">17</xref>). In this case, the protection induced was dependent on both CD4<sup>&#x0002b;</sup> and CD8<sup>&#x0002b;</sup> T cells, as  depletion of either subset at the time of tumor challenge  abrogated the ability to control tumor outgrowth. Simultaneous vaccination with a tumor-specific CTL epitope and  the tumor-specific Th epitope, rather than an unrelated Th  epitope, resulted in strong synergistic protection. Taken together, these findings illustrate the relevance of identifying  and using tumor-specific Th epitopes even in the case of  MHC class II&#x02013;negative tumors, and emphasize the importance of activating both tumor-specific CD8<sup>&#x0002b;</sup> and CD4<sup>&#x0002b;</sup>  cells to establish optimal immunity to cancer.</p></sec><sec><title>Orchestration of the Antitumor Immune Response by CD4<sup>&#x0002b;</sup> T  Cells.</title><p>As evident from the experience in the MuLV tumor models, tumor-specific CD4<sup>&#x0002b;</sup> T cells can mediate several functions influencing the outcome of tumor-specific  immunity. Numerous studies have focussed on the role  CD4<sup>&#x0002b;</sup> T cells play in delivery of help for priming of tumor-specific CTLs, resulting in important mechanistic insights into this event. Accumulating evidence indicates that  for induction of MHC class I&#x02013;restricted tumor-specific immunity, cross-presentation of antigens that have been captured by professional APCs plays a dominant role (<xref ref-type="bibr" rid="B18">18</xref>&#x02013;<xref ref-type="bibr" rid="B21">21</xref>).  Dissection of the cellular interactions involved in CTL  priming revealed that Th cells must recognize antigen on  the same APC that cross-presents the CTL epitope (<xref ref-type="bibr" rid="B22">22</xref>).  These findings explain the requirement for epitope linkage  between Th cell epitopes and CTL epitopes important for  induction of CTL responses (<xref ref-type="bibr" rid="B23">23</xref>), and could clarify the  view that help for CTLs is delivered through the release of  soluble factors such as IL-2 produced by Th cells in the  proximity of CTLs. Recently, however, it was shown that  T cell help for CTLs is critically dependent on interaction  between CD40L expressed by Th cells and CD40 expressed by APCs (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B25">25</xref>). Indeed, a central role for CD40&#x02013; CD40L interactions in the generation of protective T cell&#x02013; mediated tumor immunity has been demonstrated (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>).  These interactions most likely empower the APCs to prime  CTLs, since help for CTL priming can be bypassed by activation of dendritic cells (DCs) through CD40 (<xref ref-type="bibr" rid="B28">28</xref>). Several  lines of evidence indicate that CD40 signaling is part of an  important pathway in T cell&#x02013;dependent APC activation.  Recombinant soluble CD40L stimulates human monocytes  to release proinflammatory cytokines (<xref ref-type="bibr" rid="B29">29</xref>), whereas ligation  of CD40 on DCs or interactions between DCs and CD4<sup>&#x0002b;</sup>  T cells triggers the production of IL-12. In the latter case,  IL-12 production by DCs was inhibited by blockade of  CD40L on the CD4<sup>&#x0002b;</sup> T cell (<xref ref-type="bibr" rid="B30">30</xref>). Moreover, CD40 ligation is a potent stimulus to upregulate the expression of  intercellular adhesion molecule 1 (ICAM-1), CD80, and  CD86 molecules (<xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B32">32</xref>). Because CD40-induced activation of professional APCs results in the expression of costimulatory molecules important for CTL priming, this activation is likely to play an important role in the delivery of  T help to CTLs. In this model, the APC that cross-presents  antigen to both antigen-specific Th cells and CTLs acts as  an intermediary for the delivery of help to CTLs.</p><p>Appreciation of the fundamental role of the APC activation state to tune the outcome of T cell responsiveness  helps to explain why CTL responses against tumors, including those induced by noninflammatory persistent tumor viruses such as MuLV (and likely human papillomavirus and Epstein-Barr virus), are dependent on T cell help,  whereas CTL responsiveness against acute disease-causing  cytopathic viruses such as influenza virus is without a clear  need for CD4<sup>&#x0002b;</sup> Th activity (<xref ref-type="bibr" rid="B33">33</xref>). The difference between  these two situations appears to reside in the fact that influenza virus can directly infect and activate DCs to a phenotype conducive to CTL activation in a CD4<sup>&#x0002b;</sup> T cell&#x02013;independent fashion (<xref ref-type="bibr" rid="B28">28</xref>). However, under noninflammatory  conditions, such as in many allograft situations and in most  cancers, CTL responses are much more Th cell dependent  because DCs need to be activated first by specific CD4<sup>&#x0002b;</sup> T  cells before they trigger T killer responses.</p><p>Besides their intimate involvement in priming tumor-specific CTLs, CD4<sup>&#x0002b;</sup> Th cells participate in additional effector functions. Evidence that these other Th cell&#x02013;dependent effector mechanisms play an important role in the host  defence against tumors came from studies in the MuLV system in which adoptively transferred tumor-specific CD4<sup>&#x0002b;</sup>  T cells are implicated in the activation of tumoricidal macrophages involved in tumor clearance (<xref ref-type="bibr" rid="B15">15</xref>). More recently,  it was demonstrated in a model involving vaccination with  irradiated tumor cells, transduced to secrete GM-CSF, that  cytokines produced by CD4<sup>&#x0002b;</sup> T cells belonging to the Th1  or Th2 lineage can recruit and activate macrophages and  eosinophils, respectively (<xref ref-type="bibr" rid="B13">13</xref>). Protection against tumor  challenge was strongly associated with the presence of eosinophils at the tumor challenge site as well as the production  of oxygen radicals by tumoricidal macrophages, since genetically modified mice disabled to produce these radicals  were severely hampered in their ability to resist tumor  challenge. A significant fraction of CD8 knockout, but not  CD4 knockout animals, were able to successfully resist tumor challenge, indicating that the observed effects relied  on CD4<sup>&#x0002b;</sup> T cell&#x02013;mediated effector mechanisms.</p><p>As in the MuLV system, the tumor described above did  not express MHC class II molecules, emphasizing the notion that induction or propagation of CD4<sup>&#x0002b;</sup> T cell&#x02013;mediated immunity can be successfully applied to counteract tumors that lack or lose expression of MHC molecules.</p></sec><sec><title>Induction of Tumor-specific T Cell Tolerance.</title><p>The studies  described above, together with the identification of new  tumor antigens recognized by CD4<sup>&#x0002b;</sup> T cells, bring fresh  encouragement to the development of anticancer immune  intervention schemes. However, manipulation of the immune response to tumors in tumor-bearing hosts might be  actively frustrated by the tumor itself, as it has been reported that tumors can induce tumor-specific CD4<sup>&#x0002b;</sup> T cell  nonresponsiveness (<xref ref-type="bibr" rid="B34">34</xref>). The mechanism of tolerization is,  as yet, not clear, but it might mimic many aspects described  for tolerance induction to peripheral tissue antigens. Peripheral tolerance induction of both antigen-specific CD4<sup>&#x0002b;</sup>  and CD8<sup>&#x0002b;</sup> T cells to antigens expressed outside the lymphoid system has been described in several models (<xref ref-type="bibr" rid="B35">35</xref>&#x02013;<xref ref-type="bibr" rid="B37">37</xref>).  In these cases, tolerance is mediated by cross-presentation  of the antigen on bone marrow&#x02013;derived APCs (<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>). As  development and growth of tumors is initially not accompanied by inflammatory stimuli or stress to the immune  system, antigen derived from the tumor might be shunted  in the same cross-tolerizing pathway as reported for peripheral tissue antigens. In this way tumors, as close mimics of  the normal tissue from which they are derived, might  shrewdly use the T cell tolerizing state of certain bone marrow&#x02013;derived APCs that normally guarantee tissue tolerance. This tolerization of both helpers and killers might  hamper immune intervention schemes that are based on  the induction or propagation of the T cell immune system  in tumor-bearing hosts. Knowledge about the epitopes recognized by human tumor-specific CD4<sup>&#x0002b;</sup> and CD8<sup>&#x0002b;</sup> T cells  will be instrumental to study whether such a scenario could  explain why certain tumors&#x02014;for instance, melanoma&#x02014;are  able to grow, despite the expression of potentially highly  immunogenic tumor antigens.</p><p>In summary, tumor-specific CD4<sup>&#x0002b;</sup> Th cells can orchestrate several effector functions that can cooperate in an effective antitumor response. Knowledge of the antigens and  peptides recognized by human CD4<sup>&#x0002b;</sup> T cells is of crucial  importance for a better understanding of the behavior and  role these cells play in the immune response to human tumors, as well as for optimal use of the Th arm of the  immune system in the development of new anticancer  vaccine modalities. The studies published in this issue describing new MHC class II&#x02013;restricted melanoma antigens  and new methods to identify tumor antigens recognized by  CD4<sup>&#x0002b;</sup> T cells point to the vital role CD4<sup>&#x0002b;</sup> T cells have in  immune attack directed against human tumors, and will be  of great benefit in optimizing tumor immunotherapy if the  rules of the murine models apply to the situation in cancer  patients.</p></sec></body><back><ack><p>We thank Dr. H.G. Rammensee and Dr. T.H.M. Ottenhoff for critical reading of the manuscript.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Halder</surname><given-names>T</given-names></name><name><surname>Pawelec</surname><given-names>G</given-names></name><name><surname>Kirkin</surname><given-names>AF</given-names></name><name><surname>Zeuthen</surname><given-names>J</given-names></name><name><surname>Meyer</surname><given-names>HE</given-names></name><name><surname>Kun</surname><given-names>L</given-names></name><name><surname>Kalbacher</surname><given-names>H</given-names></name></person-group><article-title>Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3</article-title><source>Cancer Res</source><year>1997</year><volume>57</volume><fpage>3238</fpage><lpage>3244</lpage><pub-id pub-id-type="pmid">9242455</pub-id></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Topalian</surname><given-names>SL</given-names></name><name><surname>Gonzales</surname><given-names>MI</given-names></name><name><surname>Parkhurst</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>YF</given-names></name><name><surname>Southwood</surname><given-names>S</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name><name><surname>Robbins</surname><given-names>PF</given-names></name></person-group><article-title>Melanoma-specific CD4<sup>&#x0002b;</sup>T cells recognize nonmutated HLA-DR&#x02013;restricted tyrosinase epitopes</article-title><source>J Exp Med</source><year>1996</year><volume>183</volume><fpage>1965</fpage><lpage>1971</lpage><pub-id pub-id-type="pmid">8642306</pub-id></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Manici</surname><given-names>S</given-names></name><name><surname>Sturniolo</surname><given-names>T</given-names></name><name><surname>Imro</surname><given-names>MA</given-names></name><name><surname>Hammer</surname><given-names>J</given-names></name><name><surname>Sinigaglia</surname><given-names>F</given-names></name><name><surname>Noppen</surname><given-names>C</given-names></name><name><surname>Spagnoli</surname><given-names>G</given-names></name><name><surname>Mazzi</surname><given-names>B</given-names></name><name><surname>Bellone</surname><given-names>M</given-names></name><name><surname>Dellabona</surname><given-names>P</given-names></name><name><surname>Protti</surname><given-names>MP</given-names></name></person-group><article-title>Melanoma cells present a  MAGE-3 epitope to CD4<sup>&#x0002b;</sup>cytotoxic T cells in association with histocompatibility leukocyte antigen DR11</article-title><source>J Exp  Med</source><year>1999</year><volume>189</volume><fpage>871</fpage><lpage>876</lpage><pub-id pub-id-type="pmid">10049951</pub-id></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pieper</surname><given-names>R</given-names></name><name><surname>Christian</surname><given-names>RE</given-names></name><name><surname>Gonzales</surname><given-names>MI</given-names></name><name><surname>Nishimura</surname><given-names>MI</given-names></name><name><surname>Gupta</surname><given-names>G</given-names></name><name><surname>Settlage</surname><given-names>RE</given-names></name><name><surname>Shabanowitz</surname><given-names>J</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name><name><surname>Hunt</surname><given-names>DF</given-names></name><name><surname>Topalian</surname><given-names>SL</given-names></name></person-group><article-title>Biochemical identification of a mutated human melanoma antigen recognized by  CD4<sup>&#x0002b;</sup>T cells</article-title><source>J Exp Med</source><year>1999</year><volume>189</volume><fpage>757</fpage><lpage>765</lpage><pub-id pub-id-type="pmid">10049939</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chaux</surname><given-names>P</given-names></name><name><surname>Vantomme</surname><given-names>V</given-names></name><name><surname>Stroobant</surname><given-names>V</given-names></name><name><surname>Thielemans</surname><given-names>K</given-names></name><name><surname>Corthals</surname><given-names>J</given-names></name><name><surname>Luiten</surname><given-names>R</given-names></name><name><surname>Eggermont</surname><given-names>AMM</given-names></name><name><surname>Boon</surname><given-names>T</given-names></name><name><surname>van der Bruggen</surname><given-names>P</given-names></name></person-group><article-title>Identification of MAGE-3 epitopes  presented by HLA-DR molecules to CD4<sup>&#x0002b;</sup>T lymphocytes</article-title><source>J Exp Med</source><year>1999</year><volume>189</volume><fpage>767</fpage><lpage>777</lpage><pub-id pub-id-type="pmid">10049940</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Melief</surname><given-names>CJM</given-names></name></person-group><article-title>Tumor eradication by adoptive transfer of cytotoxic T lymphocytes</article-title><source>Adv Cancer Res</source><year>1992</year><volume>58</volume><fpage>143</fpage><lpage>175</lpage><pub-id pub-id-type="pmid">1532109</pub-id></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kast</surname><given-names>WM</given-names></name><name><surname>Bronkhorst</surname><given-names>AM</given-names></name><name><surname>de Waal</surname><given-names>LP</given-names></name><name><surname>Melief</surname><given-names>CJM</given-names></name></person-group><article-title>Cooperation between cytotoxic and helper T lymphocytes in protection against lethal sendai virus infection</article-title><source>J Exp Med</source><year>1986</year><volume>164</volume><fpage>723</fpage><lpage>738</lpage><pub-id pub-id-type="pmid">3018121</pub-id></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bear</surname><given-names>HD</given-names></name><name><surname>Susskind</surname><given-names>BM</given-names></name><name><surname>Close</surname><given-names>KA</given-names></name><name><surname>Barrett</surname><given-names>SK</given-names></name></person-group><article-title>Phenotype of syngeneic tumor-specific cytotoxic T lymphocytes and requirements for their in vivo generation from tumor-bearing host and immune spleens</article-title><source>Cancer Res</source><year>1988</year><volume>48</volume><fpage>1422</fpage><lpage>1427</lpage><pub-id pub-id-type="pmid">2964266</pub-id></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kast</surname><given-names>WM</given-names></name><name><surname>Offringa</surname><given-names>R</given-names></name><name><surname>Peters</surname><given-names>PJ</given-names></name><name><surname>Voordouw</surname><given-names>AC</given-names></name><name><surname>Meloen</surname><given-names>RH</given-names></name><name><surname>Van der Eb</surname><given-names>AJ</given-names></name><name><surname>Melief</surname><given-names>CJM</given-names></name></person-group><article-title>Eradication of adenovirus E1-induced tumors by E1a-specific cytotoxic T lymphocytes</article-title><source>Cell</source><year>1989</year><volume>59</volume><fpage>603</fpage><lpage>615</lpage><pub-id pub-id-type="pmid">2555063</pub-id></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greenberg</surname><given-names>PD</given-names></name><name><surname>Cheever</surname><given-names>MA</given-names></name><name><surname>Fefer</surname><given-names>A</given-names></name></person-group><article-title>Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred  immune syngeneic Lyt1<sup>&#x0002b;</sup>2<sup>&#x02212;</sup>lymphocytes</article-title><source>J Exp Med</source><year>1981</year><volume>154</volume><fpage>952</fpage><lpage>963</lpage><pub-id pub-id-type="pmid">6974221</pub-id></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schild</surname><given-names>H</given-names></name><name><surname>Kyewski</surname><given-names>B</given-names></name><name><surname>Von Hoegen</surname><given-names>P</given-names></name><name><surname>Schirrmacher</surname><given-names>V</given-names></name></person-group><article-title>CD4&#x0002b; helper T cells are required for resistance to highly metastatic murine tumor</article-title><source>Eur J Immunol</source><year>1987</year><volume>17</volume><fpage>1863</fpage><lpage>1866</lpage><pub-id pub-id-type="pmid">2961578</pub-id></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Romerdahl</surname><given-names>CA</given-names></name><name><surname>Kripke</surname><given-names>ML</given-names></name></person-group><article-title>Role of helper T-lymphocytes in rejection of UV-induced murine skin cancers</article-title><source>Cancer Res</source><year>1988</year><volume>48</volume><fpage>2325</fpage><lpage>2328</lpage><pub-id pub-id-type="pmid">2965612</pub-id></citation></ref><ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>K</given-names></name><name><surname>Hayashi</surname><given-names>R</given-names></name><name><surname>Lafond-Walker</surname><given-names>A</given-names></name><name><surname>Lowenstein</surname><given-names>C</given-names></name><name><surname>Pardoll</surname><given-names>D</given-names></name><name><surname>Levitsky</surname><given-names>H</given-names></name></person-group><article-title>The central role of CD4<sup>&#x0002b;</sup>T cells in the antitumor immune response</article-title><source>J Exp Med</source><year>1998</year><volume>188</volume><fpage>2357</fpage><lpage>2368</lpage><pub-id pub-id-type="pmid">9858522</pub-id></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Keene</surname><given-names>J</given-names></name><name><surname>Forman</surname><given-names>J</given-names></name></person-group><article-title>Helper activity is required for the in vivo generation of cytotoxic T lymphocytes</article-title><source>J Exp  Med</source><year>1982</year><volume>155</volume><fpage>768</fpage><lpage>782</lpage><pub-id pub-id-type="pmid">6801178</pub-id></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greenberg</surname><given-names>PD</given-names></name></person-group><article-title>Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells</article-title><source>Adv Immunol</source><year>1991</year><volume>49</volume><fpage>281</fpage><lpage>355</lpage><pub-id pub-id-type="pmid">1853786</pub-id></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greenberg</surname><given-names>PD</given-names></name><name><surname>Kern</surname><given-names>DE</given-names></name><name><surname>Cheever</surname><given-names>MA</given-names></name></person-group><article-title>Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1<sup>&#x0002b;</sup>,2<sup>&#x02212;</sup>T cells. Tumor eradication does not require participation of cytotoxic T cells</article-title><source>J Exp  Med</source><year>1985</year><volume>161</volume><fpage>1122</fpage><lpage>1134</lpage><pub-id pub-id-type="pmid">3921652</pub-id></citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ossendorp</surname><given-names>F</given-names></name><name><surname>Menged</surname><given-names>E</given-names></name><name><surname>Camps</surname><given-names>M</given-names></name><name><surname>Filius</surname><given-names>R</given-names></name><name><surname>Melief</surname><given-names>CJM</given-names></name></person-group><article-title>Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II&#x02013;negative tumors</article-title><source>J Exp Med</source><year>1998</year><volume>187</volume><fpage>693</fpage><lpage>702</lpage><pub-id pub-id-type="pmid">9480979</pub-id></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bevan</surname><given-names>MJ</given-names></name></person-group><article-title>Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay</article-title><source>J Exp Med</source><year>1976</year><volume>143</volume><fpage>1283</fpage><lpage>1288</lpage><pub-id pub-id-type="pmid">1083422</pub-id></citation></ref><ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seung</surname><given-names>S</given-names></name><name><surname>Urban</surname><given-names>JL</given-names></name><name><surname>Schreiber</surname><given-names>H</given-names></name></person-group><article-title>A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8<sup>&#x0002b;</sup>T cells to an antigen that no longer serves as a target</article-title><source>J Exp Med</source><year>1993</year><volume>178</volume><fpage>933</fpage><lpage>940</lpage><pub-id pub-id-type="pmid">8394406</pub-id></citation></ref><ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>AYC</given-names></name><name><surname>Golumbek</surname><given-names>P</given-names></name><name><surname>Ahmadzadeh</surname><given-names>M</given-names></name><name><surname>Jaffee</surname><given-names>E</given-names></name><name><surname>Pardoll</surname><given-names>D</given-names></name><name><surname>Levitsky</surname><given-names>H</given-names></name></person-group><article-title>Role of bone marrow- derived cells in presenting MHC class I-restricted tumor antigens</article-title><source>Science</source><year>1994</year><volume>264</volume><fpage>961</fpage><lpage>965</lpage><pub-id pub-id-type="pmid">7513904</pub-id></citation></ref><ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Toes</surname><given-names>REM</given-names></name><name><surname>Blom</surname><given-names>RJJ</given-names></name><name><surname>van der Voort</surname><given-names>E</given-names></name><name><surname>Offringa</surname><given-names>R</given-names></name><name><surname>Melief</surname><given-names>CJM</given-names></name><name><surname>Kast</surname><given-names>WM</given-names></name></person-group><article-title>Protective anti-tumor immunity induced by immunization with completely allogeneic tumor cells</article-title><source>Cancer Res</source><year>1996</year><volume>56</volume><fpage>3782</fpage><lpage>3783</lpage><pub-id pub-id-type="pmid">8706024</pub-id></citation></ref><ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bennett</surname><given-names>SRM</given-names></name><name><surname>Carbone</surname><given-names>FR</given-names></name><name><surname>Karamalis</surname><given-names>F</given-names></name><name><surname>Miller</surname><given-names>JFAP</given-names></name><name><surname>Heath</surname><given-names>WR</given-names></name></person-group><article-title>Induction of a CD8<sup>&#x0002b;</sup> cytotoxic T lymphocyte response by cross-priming requires cognate CD4<sup>&#x0002b;</sup>T cell help</article-title><source>J Exp Med</source><year>1997</year><volume>186</volume><fpage>65</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">9206998</pub-id></citation></ref><ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cassel</surname><given-names>D</given-names></name><name><surname>Forman</surname><given-names>J</given-names></name></person-group><article-title>Linked recognition of helper and cytotoxic antigenic determinants for the generation of cytotoxic T lymphocytes</article-title><source>Ann NY Acad Sci</source><year>1988</year><volume>532</volume><fpage>51</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">2460011</pub-id></citation></ref><ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schoenberger</surname><given-names>SP</given-names></name><name><surname>Toes</surname><given-names>REM</given-names></name><name><surname>van der Voort</surname><given-names>EIH</given-names></name><name><surname>Offringa</surname><given-names>R</given-names></name><name><surname>Melief</surname><given-names>CJM</given-names></name></person-group><article-title>T help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions</article-title><source>Nature</source><year>1998</year><volume>393</volume><fpage>480</fpage><lpage>483</lpage><pub-id pub-id-type="pmid">9624005</pub-id></citation></ref><ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bennet</surname><given-names>SRM</given-names></name><name><surname>Carbone</surname><given-names>FR</given-names></name><name><surname>Karamalis</surname><given-names>F</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name><name><surname>Miller</surname><given-names>JFAP</given-names></name><name><surname>Heath</surname><given-names>WR</given-names></name></person-group><article-title>Help for cytotoxic T cell responses is mediated by CD40 signalling</article-title><source>Nature</source><year>1998</year><volume>393</volume><fpage>478</fpage><lpage>480</lpage><pub-id pub-id-type="pmid">9624004</pub-id></citation></ref><ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mackey</surname><given-names>MF</given-names></name><name><surname>Gunn</surname><given-names>JR</given-names></name><name><surname>Ting</surname><given-names>PP</given-names></name><name><surname>Kikutani</surname><given-names>H</given-names></name><name><surname>Dranoff</surname><given-names>G</given-names></name><name><surname>Noelle</surname><given-names>RJ</given-names></name><name><surname>Barth</surname><given-names>RJ</given-names><suffix>Jr</suffix></name></person-group><article-title>Protective immunity induced by tumor vaccines requires interactions between CD40 and its ligand, CD154</article-title><source>Cancer Res</source><year>1997</year><volume>57</volume><fpage>2569</fpage><lpage>2574</lpage><pub-id pub-id-type="pmid">9205055</pub-id></citation></ref><ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mackey</surname><given-names>MF</given-names></name><name><surname>Gunn</surname><given-names>JR</given-names></name><name><surname>Maliszewski</surname><given-names>C</given-names></name><name><surname>Kikutani</surname><given-names>H</given-names></name><name><surname>Noelle</surname><given-names>RJ</given-names></name><name><surname>Barth</surname><given-names>RJ</given-names><suffix>Jr</suffix></name></person-group><article-title>Dendritic cells require maturation via CD40 to generate protective antitumor immunity</article-title><source>J Immunol</source><year>1998</year><volume>161</volume><fpage>2094</fpage><lpage>2098</lpage><pub-id pub-id-type="pmid">9725199</pub-id></citation></ref><ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ridge</surname><given-names>JP</given-names></name><name><surname>Di Rosa</surname><given-names>F</given-names></name><name><surname>Matzinger</surname><given-names>P</given-names></name></person-group><article-title>A conditioned dendritic cell can be a temporal bridge between a CD4&#x0002b; T-helper and a T-killer cell</article-title><source>Nature</source><year>1998</year><volume>393</volume><fpage>474</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">9624003</pub-id></citation></ref><ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kiener</surname><given-names>PA</given-names></name><name><surname>Moran</surname><given-names>DP</given-names></name><name><surname>Rankin</surname><given-names>BM</given-names></name><name><surname>Wahl</surname><given-names>AF</given-names></name><name><surname>Aruffo</surname><given-names>A</given-names></name><name><surname>Hollenbaugh</surname><given-names>D</given-names></name></person-group><article-title>Stimulation with purified soluble CD40L induces proinflammatory responses in human monocytes</article-title><source>J Immunol</source><year>1995</year><volume>155</volume><fpage>4917</fpage><lpage>4925</lpage><pub-id pub-id-type="pmid">7594496</pub-id></citation></ref><ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>F</given-names></name><name><surname>Stanzl</surname><given-names>U</given-names></name><name><surname>Jennewein</surname><given-names>P</given-names></name><name><surname>Janke</surname><given-names>K</given-names></name><name><surname>Heufler</surname><given-names>C</given-names></name><name><surname>Kampgen</surname><given-names>E</given-names></name><name><surname>Romani</surname><given-names>N</given-names></name><name><surname>Schuler</surname><given-names>G</given-names></name></person-group><article-title>High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10</article-title><source>J Exp Med</source><year>1996</year><volume>184</volume><fpage>741</fpage><lpage>746</lpage><pub-id pub-id-type="pmid">8760828</pub-id></citation></ref><ref id="B31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cella</surname><given-names>M</given-names></name><name><surname>Scheidegger</surname><given-names>D</given-names></name><name><surname>Palmer-Lehmann</surname><given-names>K</given-names></name><name><surname>Lane</surname><given-names>P</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name><name><surname>Alber</surname><given-names>G</given-names></name></person-group><article-title>Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T&#x02013;T help via APC activation</article-title><source>J Exp Med</source><year>1996</year><volume>184</volume><fpage>747</fpage><lpage>752</lpage><pub-id pub-id-type="pmid">8760829</pub-id></citation></ref><ref id="B32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shinde</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Niu</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Grewal</surname><given-names>IS</given-names></name><name><surname>Flavell</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name></person-group><article-title>CD40L is important for induction of, but not response to, costimulatory activity. ICAM-1 as the second costimulatory molecule rapidly upregulated by CD40L</article-title><source>J Immunol</source><year>1996</year><volume>157</volume><fpage>2764</fpage><lpage>2768</lpage><pub-id pub-id-type="pmid">8816378</pub-id></citation></ref><ref id="B33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Allan</surname><given-names>W</given-names></name><name><surname>Tabi</surname><given-names>Z</given-names></name><name><surname>Cleary</surname><given-names>A</given-names></name><name><surname>Doherty</surname><given-names>PC</given-names></name></person-group><article-title>Cellular events in the lymph node and lung with influenza. Consequences of depleting CD4&#x0002b; T cells</article-title><source>J Immunol</source><year>1990</year><volume>144</volume><fpage>3980</fpage><lpage>3986</lpage><pub-id pub-id-type="pmid">1692070</pub-id></citation></ref><ref id="B34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Staveley-O'Carroll</surname><given-names>K</given-names></name><name><surname>Sotomayor</surname><given-names>E</given-names></name><name><surname>Montgomery</surname><given-names>J</given-names></name><name><surname>Borrello</surname><given-names>I</given-names></name><name><surname>Hwang</surname><given-names>L</given-names></name><name><surname>Fein</surname><given-names>S</given-names></name><name><surname>Pardoll</surname><given-names>D</given-names></name><name><surname>Levitsky</surname><given-names>H</given-names></name></person-group><article-title>Induction of antigen-specific T cell anergy: an early event in the course of tumor progression</article-title><source>Proc Natl Acad  Sci USA</source><year>1998</year><volume>95</volume><fpage>1178</fpage><lpage>1183</lpage><pub-id pub-id-type="pmid">9448305</pub-id></citation></ref><ref id="B35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname><given-names>I</given-names></name><name><surname>Lieberam</surname><given-names>I</given-names></name></person-group><article-title>Peripheral tolerance of CD4 T cells following local activation in adolescent mice</article-title><source>Eur J Immunol</source><year>1996</year><volume>26</volume><fpage>3194</fpage><lpage>3202</lpage><pub-id pub-id-type="pmid">8977322</pub-id></citation></ref><ref id="B36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kurts</surname><given-names>C</given-names></name><name><surname>Kosaka</surname><given-names>H</given-names></name><name><surname>Carbone</surname><given-names>FR</given-names></name><name><surname>Miller</surname><given-names>JFAP</given-names></name><name><surname>Heath</surname><given-names>WR</given-names></name></person-group><article-title>Class I&#x02013;restricted cross-presentation of  exogenous self-antigens leads to deletion of autoreactive  CD8<sup>&#x0002b;</sup>T cells</article-title><source>J Exp Med</source><year>1997</year><volume>186</volume><fpage>239</fpage><lpage>245</lpage><pub-id pub-id-type="pmid">9221753</pub-id></citation></ref><ref id="B37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adler</surname><given-names>AJ</given-names></name><name><surname>Marsh</surname><given-names>DW</given-names></name><name><surname>Yochum</surname><given-names>GS</given-names></name><name><surname>Guzzo</surname><given-names>JL</given-names></name><name><surname>Nigam</surname><given-names>A</given-names></name><name><surname>Nelson</surname><given-names>WG</given-names></name><name><surname>Pardoll</surname><given-names>DW</given-names></name></person-group><article-title>CD4<sup>&#x0002b;</sup>T cell tolerance to parenchymal self-antigens requires presentation by bone-marrow&#x02013;derived antigen-presenting cells</article-title><source>J Exp  Med</source><year>1998</year><volume>187</volume><fpage>1555</fpage><lpage>1564</lpage><pub-id pub-id-type="pmid">9584134</pub-id></citation></ref></ref-list><fn-group><fn><p>R.E.M. Toes is a fellow of the Royal Netherlands Academy of Arts and Sciences.</p></fn></fn-group></back></article>


